Roche KAPA Target Enrichment Portfolio
Roche launched its new KAPA Target Enrichment product portfolio, which includes both exome and custom target enrichment solutions for sequencing. The KAPA HyperExome is a whole-exome research panel with improved performance compared to the existing SeqCap portfolio that targets the GRCh38/hg38 geome assembly. Roche's HyperDesign tool allows for the creation of custom target enrichment designs using the KAPA HyperChoice probes. The target enrichment portfolio will increase sequencing efficiency, the company said. The new probes replace the discontinued SeqCap product portfolio, although Roche said it will support the discontinued product until the first quarter of 2022.
Beckman Coulter Life Sciences RNAdvance Viral XP
Beckman Coulter Life Sciences announced the launch of its new RNA extraction kit, RNAdvance Viral XP. The kit is validated for use in infectious disease and real-time PCR virus research and is intended for use in high-throughput settings to extract viral RNA from swab samples, the firm said. After it has been extracted, the RNA is used in qRT-PCR kits to determine whether the virus is present. Danaher subsidiary Beckman Coulter worked with next-generation sequencing company iRepertoire to develop the kit's method, which iRepertoire then independently validated.
LGC SARS-CoV-2 Verification Panel and Reference Materials; Charité ValuPanel Assay Reagents
LGC Seracare has launched new versions of its AccuPlex Verification Panel and Reference Material Kit for SARS-CoV-2 testing. The previous versions contained negative control material targeting the human RNase P gene and positive control material for the viral ORF1a, RdRp, E, and N gene consensus sequences targeted in the US Centers for Disease Control and Prevention and World Health Organization assays. They have now been expanded to include the S gene region of the virus.
In addition, LGC, Biosearch Technologies has launched new assays in its ValuPanel line. The Charité 2019-nCoV BHQ and BBQ-650 ValuPanel Reagent sets use oligonucleotide sequences designed by the German Center for Infection Research (DZIF) at Charité. The firm also now offers US CDC 2019-nCoV BHQ ValuPanel Reagents sets, and continues to offer the 2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2.
For more new products and services, please visit the New Products page on our website.